Objective： To evaluate the efficacy and safety of recombinant human interleukin-11 （rhIL-11） for the chemotherapy-induced thrombocytopenia in patients with gastrointestinal cancer. Methods： It was an opened and no...Objective： To evaluate the efficacy and safety of recombinant human interleukin-11 （rhIL-11） for the chemotherapy-induced thrombocytopenia in patients with gastrointestinal cancer. Methods： It was an opened and non-randomized controlled clinical study. When the platelet counts was under 75 × 10^9/L after chemotherapy, rhlL-11 was administered 25 μg/（kg·d） as a daily SC injection last for 7-14 days, or discontinued when platelet counts 〉 100 × 10^9/L. Results： Seventysix patients were enrolled into this study. The treatment group and the control group had thirty-eight cases, respectively. The mean recovery time to PLT ≥ 100 × 10^9/L was 8.1 days in treatment group, while in control group was 12.2 days （P 〈 0.01）. Moreover, the mean recovery time from PLT 〈_ 50 × 10^9/L to 〉 100 × 10^9/L was 8.9 days in treatment group, while in control group was 12.9 days （P 〈 0.05）. There was a statistical difference between the two groups. Major side effects included edema, fever, articular muscle soreness, but they were all mild and well tolerable. Conclusion： rhIL-11 can be safely and effectively used for the treatment of chemotherapy-induced thrombocytopenia in patients with gastrointestinal cancer.展开更多
目的:观察重组人白介素-11治疗由化疗引起的血小板减少症的临床疗效及安全性。方法:选取化疗引起的血小板减少症患者86例,按随机数字表法分为对照组和观察组,各43例。对照组患者输注血小板10 IU,2~3 d 1次;观察组患者给予注射用重组人...目的:观察重组人白介素-11治疗由化疗引起的血小板减少症的临床疗效及安全性。方法:选取化疗引起的血小板减少症患者86例,按随机数字表法分为对照组和观察组,各43例。对照组患者输注血小板10 IU,2~3 d 1次;观察组患者给予注射用重组人白介素-11,25~50μg/kg,qd。两组患者均治疗14 d。观察两组患者临床疗效及治疗前后血小板计数,并比较两组患者血小板减少持续与恢复时间,以及不良反应发生情况。结果:观察组患者临床总有效率为81.40%,显著高于对照组的62.79%,差异有统计学意义(P<0.05)。两组患者治疗前血小板计数比较,差异无统计学意义(P>0.05);治疗后,两组患者血小板计数均显著升高,且观察组显著高于对照组,差异均有统计学意义(P<0.05)。观察组患者血小板<50×10~9L^(-1)持续时间,恢复至70×10~9L^(-1)和100×10~9L^(-1)时间均显著短于对照组,差异均有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:重组人白介素-11治疗化疗引起的血小板减少症有较好的疗效,能明显改善患者血小板计数,缩短血小板减少持续与恢复时间,且安全性较好。展开更多
目的探讨重组人白介素-11（recombinant human interleukin-11,rhIL-11）及重组人血小板生成素（recombinant human thrombopoietin,rhTPO）在治疗肝硬化脾功能亢进所致血小板减少的临床疗效及差异.方法选取肝硬化脾功能亢进所致血小板...目的探讨重组人白介素-11（recombinant human interleukin-11,rhIL-11）及重组人血小板生成素（recombinant human thrombopoietin,rhTPO）在治疗肝硬化脾功能亢进所致血小板减少的临床疗效及差异.方法选取肝硬化脾功能亢进所致血小板减少（PLT≤75×10^9/L）的患者66例分为两组,一组接受皮下注射rhIL-11 3 mg/次,qd;另一组接受皮下注射rhTPO 15000μg/次,qd;观察及比较两组治疗效果.结果rhIL-11和rhTPO两个治疗组入组例数分别为42例和24例,rhIL-11和rhTPO治疗后血小板数值均较治疗前增高（P〈0.05）,rhIL-11和rhTPO两组平均升高幅度分别为5.95×10^9/L±12.31×10^9/L、45.92×10^9/L±37.47×10^9/L;rhIL-11治疗的第10天血小板较治疗前明显改善（P〈0.05）,而rhTPO治疗的第7天血小板数值就较治疗前明显升高（P〈0.05）;两组均在治疗开始的第3天血小板计数开始升高,在第10天达到最大值,rhIL-11组第3、5、7、10天的血小板相比治疗前分别增长了4%、18%、21%、50%,相比治疗前,rhTPO组第3、5、7、10天的血小板分别增长了39%、84%、145%、267%;对于重度血小板减少患者,rhIL-11治疗前后血小板差异无统计学意义;在重度血小板减少患者中,rhTPO治疗后血小板数值较治疗前升高,差异具有统计学意义（P〈0.05）;rhI L-11与rhTPO治疗肝硬化血小板减少症的有效率分别为75%和100%,且二者之间有效率差异具有统计学意义（P〈0.05）;rhIL-11治疗后血红蛋白低于治疗前（P〈0.05）,治疗前后rhTPO对血红蛋白无影响;rhIL-11和rhTPO对治疗前后的白细胞、肝功能及凝血无影响;rhTPO不良反应发生率低于rhIL-11（P〈0.05）.结论rhIL-11与rhTPO均能短期显著升高肝硬化脾功能亢进患者血小板水平,相比rhIL-11,rhTPO提升血小板时间更快,对于重度血小板减少疗效更好,不良反应发生率更低.展开更多
文摘Objective： To evaluate the efficacy and safety of recombinant human interleukin-11 （rhIL-11） for the chemotherapy-induced thrombocytopenia in patients with gastrointestinal cancer. Methods： It was an opened and non-randomized controlled clinical study. When the platelet counts was under 75 × 10^9/L after chemotherapy, rhlL-11 was administered 25 μg/（kg·d） as a daily SC injection last for 7-14 days, or discontinued when platelet counts 〉 100 × 10^9/L. Results： Seventysix patients were enrolled into this study. The treatment group and the control group had thirty-eight cases, respectively. The mean recovery time to PLT ≥ 100 × 10^9/L was 8.1 days in treatment group, while in control group was 12.2 days （P 〈 0.01）. Moreover, the mean recovery time from PLT 〈_ 50 × 10^9/L to 〉 100 × 10^9/L was 8.9 days in treatment group, while in control group was 12.9 days （P 〈 0.05）. There was a statistical difference between the two groups. Major side effects included edema, fever, articular muscle soreness, but they were all mild and well tolerable. Conclusion： rhIL-11 can be safely and effectively used for the treatment of chemotherapy-induced thrombocytopenia in patients with gastrointestinal cancer.
文摘目的:观察重组人白介素-11治疗由化疗引起的血小板减少症的临床疗效及安全性。方法:选取化疗引起的血小板减少症患者86例,按随机数字表法分为对照组和观察组,各43例。对照组患者输注血小板10 IU,2~3 d 1次;观察组患者给予注射用重组人白介素-11,25~50μg/kg,qd。两组患者均治疗14 d。观察两组患者临床疗效及治疗前后血小板计数,并比较两组患者血小板减少持续与恢复时间,以及不良反应发生情况。结果:观察组患者临床总有效率为81.40%,显著高于对照组的62.79%,差异有统计学意义(P<0.05)。两组患者治疗前血小板计数比较,差异无统计学意义(P>0.05);治疗后,两组患者血小板计数均显著升高,且观察组显著高于对照组,差异均有统计学意义(P<0.05)。观察组患者血小板<50×10~9L^(-1)持续时间,恢复至70×10~9L^(-1)和100×10~9L^(-1)时间均显著短于对照组,差异均有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:重组人白介素-11治疗化疗引起的血小板减少症有较好的疗效,能明显改善患者血小板计数,缩短血小板减少持续与恢复时间,且安全性较好。
文摘目的探讨重组人白介素-11（recombinant human interleukin-11,rhIL-11）及重组人血小板生成素（recombinant human thrombopoietin,rhTPO）在治疗肝硬化脾功能亢进所致血小板减少的临床疗效及差异.方法选取肝硬化脾功能亢进所致血小板减少（PLT≤75×10^9/L）的患者66例分为两组,一组接受皮下注射rhIL-11 3 mg/次,qd;另一组接受皮下注射rhTPO 15000μg/次,qd;观察及比较两组治疗效果.结果rhIL-11和rhTPO两个治疗组入组例数分别为42例和24例,rhIL-11和rhTPO治疗后血小板数值均较治疗前增高（P〈0.05）,rhIL-11和rhTPO两组平均升高幅度分别为5.95×10^9/L±12.31×10^9/L、45.92×10^9/L±37.47×10^9/L;rhIL-11治疗的第10天血小板较治疗前明显改善（P〈0.05）,而rhTPO治疗的第7天血小板数值就较治疗前明显升高（P〈0.05）;两组均在治疗开始的第3天血小板计数开始升高,在第10天达到最大值,rhIL-11组第3、5、7、10天的血小板相比治疗前分别增长了4%、18%、21%、50%,相比治疗前,rhTPO组第3、5、7、10天的血小板分别增长了39%、84%、145%、267%;对于重度血小板减少患者,rhIL-11治疗前后血小板差异无统计学意义;在重度血小板减少患者中,rhTPO治疗后血小板数值较治疗前升高,差异具有统计学意义（P〈0.05）;rhI L-11与rhTPO治疗肝硬化血小板减少症的有效率分别为75%和100%,且二者之间有效率差异具有统计学意义（P〈0.05）;rhIL-11治疗后血红蛋白低于治疗前（P〈0.05）,治疗前后rhTPO对血红蛋白无影响;rhIL-11和rhTPO对治疗前后的白细胞、肝功能及凝血无影响;rhTPO不良反应发生率低于rhIL-11（P〈0.05）.结论rhIL-11与rhTPO均能短期显著升高肝硬化脾功能亢进患者血小板水平,相比rhIL-11,rhTPO提升血小板时间更快,对于重度血小板减少疗效更好,不良反应发生率更低.
